{"title":"A Patient with Gastric Metastasis of Lobular Breast Cancer with CDH1 Mutation: A Case Report","authors":"H. Wang, Z. Li, H. Zhang, Z. Yang, Jian-Yun Nie","doi":"10.47829/coo.2020.3305","DOIUrl":"https://doi.org/10.47829/coo.2020.3305","url":null,"abstract":"Gastric metastasis of breast cancer is extremely rare, diagnosed as breast cancer metastases to the stomach should distinguish between primary and metastatic tumors because of their differences in prognosis and management. Mutations in the CDH1 gene may increase the risk of this pathogenesis since E-cadherin plays a cru-cial role in both lobular breast cancer and gastric cancer.","PeriodicalId":92766,"journal":{"name":"Clinics of oncology","volume":"147 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73245225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M W Saif, D W Hackenyos, M H Smith, P Healey, V Relias, K Wasif
{"title":"Racial Differences in Accepting Pegfilgrastim Onpro Kit (On-Body Injector) Use Among Cancer Patients.","authors":"M W Saif, D W Hackenyos, M H Smith, P Healey, V Relias, K Wasif","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>1.1.Neulasta Onpro kit eliminates need for additional clinic visit after chemotherapy. Given the racially diverse population in our institution, we investigated acceptance of Onpro kit among patients on chemotherapy.</p><p><strong>Research design and methods: </strong>1.2.Single-institution, retrospective review conducted in patients with GI tumors who received Onpro kit within 1 hour of completion of systemic chemotherapy from Jan 2014 through Jan 2018. Clinic/nursing notes and pharmacy records were reviewed to identify patients who refused Onpro kit and to discern reasons for refusal, including racial reason.</p><p><strong>Results: </strong>1.3.Total 238 orders for kit were voided amongst 68 patients (Caucasian 41; African American 7; Spanish 3; Asian 17). Overall, 15/68 patients refused kit (22%) of these 87% were Asian. The reasons for refusal included dislike of bulky attachment to skin, request to place kit on stomach instead of arm, trepidation over unwitnessed administration of drug, fear of reaction, disposal at home, fear of pain, lack of confirmation of proper dose administration, and need for MRI.</p><p><strong>Conclusions: </strong>1.4.While Onpro kit is an attractive alternative, 22% of patients with voided orders, mainly of Asian race, declined its application. We believe the current study represents the first look at important racial differences in accepting Onpro kit. Consideration of patients' cultural heritage, race, ethnicity and education may facilitate communication between physicians and patients to achieve optimal cancer care.</p>","PeriodicalId":92766,"journal":{"name":"Clinics of oncology","volume":"1 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690622/pdf/nihms-1035558.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41223279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Possible Impact of a European Agency for the Strategic Management Against Cancer (EASMAC) on Treatment, Diagnosis and EU Politics","authors":"C. Melidis","doi":"10.47829/coo.2020.3201","DOIUrl":"https://doi.org/10.47829/coo.2020.3201","url":null,"abstract":"Each European Union (EU) country has its own therapeutic and diagnostic protocols for cancer treatment, contrary to the USA. In order to achieve a therapeutic and follow-up harmonization, the existence of a central EU agency can be of paramount importance. The aim of the current paper is to present the (still in paper) European Agency for the Strategic Management Against Cancer (EASMAC) and its possible impact on cancer patient treatment and diagnosis and EU politics in general.","PeriodicalId":92766,"journal":{"name":"Clinics of oncology","volume":"2022 26","pages":""},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72538310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Lutsyk, M. Caro, B. Gutiérrez, I. Turgeman, Gabriela Antel, I. Planas, Y. Luis, E. Luguera, S. Villà
{"title":"Upper Rectal Cancer: Benefit After Preoperative Chemoradiation Versus Upfront Surgery?","authors":"M. Lutsyk, M. Caro, B. Gutiérrez, I. Turgeman, Gabriela Antel, I. Planas, Y. Luis, E. Luguera, S. Villà","doi":"10.47829/coo.2022.6102","DOIUrl":"https://doi.org/10.47829/coo.2022.6102","url":null,"abstract":"Purpose: Upper rectal cancer management is controversial. The present series reports the outcomes of treatment comparing neoadjuvant chemoradiation (NCRT) versus upfront surgery. 1.2. Methods and materials: In this retrospective study we enrolled patients with upper rectal or sigmoid junction locally advanced tumors (stages II-III). At the first Institution patients received NCRT followed by surgery (study group); at the second Institution patients were referred to upfront surgery (control group). Overall survival was the main endpoint of the analysis. Local relapse and other clinical variables were also analyzed. 1.3. Results: Fifty patients in the study group and 32 patients in the control group were analyzed. In the NCRT group there were more N-positive patients (p<0.001); T-stage was similar for both groups. All surgical procedures were performed with R0 margins. Among NCRT patients, in seven cases (14%) complete pathologic response was found. In 27 cases (54%) downstaging in T-stage was achieved. Comparing OS between NCRT and control group there was no significant difference at five years: 84% for NCRT group and 79% for control group (p 0.37). In univariate analysis, clinical T-stage had a statistically significant impact on survival. Patients with cT3 disease did better than patients with cT4 (p = 0.014). Two cases of G4 toxicity were observed and only one case of local relapse was observed in NCRT group. 1.4. Conclusion: NCRT achieved a high rate of downstaging alongside tolerable toxicity profile, but did not affect survival outcome in this selected group, as compared to surgery alone.","PeriodicalId":92766,"journal":{"name":"Clinics of oncology","volume":"82 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88798798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}